Overview

Study to Evaluate the Efficacy and Safety of Immunotherapy With Axitinib in Advanced Collecting Duct Carcinoma

Status:
RECRUITING
Trial end date:
2027-02-01
Target enrollment:
Participant gender:
Summary
This is a phase II trial to evaluate the efficacy and safety of immune checkpoint inhibitors in combination with axitinib for previously treated advanced collecting duct carcinoma.
Phase:
PHASE2
Details
Lead Sponsor:
Peking University Cancer Hospital & Institute
Treatments:
Axitinib